Equillium Featured in Panel Discussion at Capital Markets Day for Kidney Health

LA JOLLA, Calif., Nov. 15, 2019 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that Krishna R. Polu, M.D., chief medical officer, will participate in a panel discussing ?New Innovations in Drug Therapy? as part of the Kidney Capital Markets Day hosted by the American Society of Nephrology (ASN) and RenalytixAI on Tuesday, November 19, 2019 in London, England.